CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 43 enrolled
Drug / intervention
AB-729 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04980482
NCT04980482Phase 2Completed
CompareCT.gov

A Randomized, Open-Label, Multicenter Study Investigating AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a Treatment in Subjects With Chronic Hepatitis B Infection

Arbutus Biopharma Corporation·interventional·Posted Jul 28, 2021·Updated Apr 29, 2026

In Brief

A Phase 2 clinical trial evaluating AB-729 and Peg-IFNα-2a for Chronic Hepatitis b. Completed, enrolled 43 participants across 17 sites in 7 countries.

Detailed Summary

This is a randomized, open label, multicenter Phase 2 study investigating the safety and antiviral activity of AB-729 in combination with ongoing NA therapy and short courses of Peg-IFNα-2a in subjects with CHB.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Hepatitis b
CountriesAustralia, Hong Kong, Moldova, South Korea, Taiwan, Ukraine, United States
Collaborators--

Timeline

Phase 2CompletedFinished
20222023202420252026
First PostedJul 28, 2021
Enrollment StartOct 29, 2021
Primary CompletionMar 13, 2025
Study CompletionMay 21, 2025
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 4.9 years ago

Interventions

AB-729drug

subcutaneous injection

Peg-IFNα-2adrug

subcutaneous injection